Among the new concepts in respiratory diseases, such as COPD and asthma, selective inhibitors of phosphodiesterase 4 (PDE4) are under scrutiny for more than two decades as new selective drugs. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.